CRESCENT BIOPHARMA, INC. Selling, General and Administrative Expense
CRESCENT BIOPHARMA, INC. (CBIO) reported Selling, General and Administrative Expense of $6.60 million for the 12-month period ending 2014-12-31, per its 10-K filed 2015-03-16.
Discontinued › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2015-03-16
- CRESCENT BIOPHARMA, INC. selling, general and administrative expense for the quarter ending 2014-12-31 was $2.12M, a 157.23% increase year-over-year.
- CRESCENT BIOPHARMA, INC. selling, general and administrative expense for the quarter ending 2014-09-30 was $1.65M, a 106.00% increase year-over-year.
- CRESCENT BIOPHARMA, INC. selling, general and administrative expense for the quarter ending 2014-06-30 was $1.61M, a 140.19% increase year-over-year.
- CRESCENT BIOPHARMA, INC. selling, general and administrative expense for the quarter ending 2014-03-31 was $1.22M, a 102.15% increase year-over-year.
- CRESCENT BIOPHARMA, INC. selling, general and administrative expense for fiscal 2014 was $6.60M, a 127.60% increase from fiscal 2013.
- CRESCENT BIOPHARMA, INC. selling, general and administrative expense for fiscal 2013 was $2.90M, a 32.70% increase from fiscal 2012.
- CRESCENT BIOPHARMA, INC. selling, general and administrative expense for fiscal 2012 was $2.18M.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 9 month | Selling, General and Administrative Expense 12 month | Selling, General and Administrative Expense 130 month |
|---|---|---|---|---|---|
| 2014-12-31 | $2.12M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-16 | $3.77M derived: sum of 2 quarters · filed 2015-03-16 | $5.37M derived: sum of 3 quarters · filed 2015-03-16 | $6.60M 10-K · filed 2015-03-16 | |
| 2014-09-30 | $1.65M 10-Q · filed 2014-10-31 | $3.25M derived: sum of 2 quarters · filed 2014-10-31 | $4.48M 10-Q · filed 2014-10-31 | $5.30M derived: sum of 4 quarters · filed 2015-03-16 | |
| 2014-06-30 | $1.61M 10-Q · filed 2014-07-31 | $2.83M 10-Q · filed 2014-07-31 | $3.65M derived: sum of 3 quarters · filed 2015-03-16 | $4.45M derived: sum of 4 quarters · filed 2015-03-16 | |
| 2014-03-31 | $1.22M 10-Q · filed 2014-05-09 | $2.05M derived: sum of 2 quarters · filed 2015-03-16 | $2.85M derived: sum of 3 quarters · filed 2015-03-16 | $3.52M derived: sum of 4 quarters · filed 2015-03-16 | $17.21M 10-Q · filed 2014-05-09 |
| 2013-12-31 | $823.09K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-16 | $1.62M derived: sum of 2 quarters · filed 2015-03-16 | $2.29M derived: sum of 3 quarters · filed 2015-03-16 | $2.90M 10-K · filed 2015-03-16 | |
| 2013-09-30 | $800.23K 10-Q · filed 2014-10-31 | $1.47M derived: sum of 2 quarters · filed 2014-10-31 | $2.07M 10-Q · filed 2014-10-31 | ||
| 2013-06-30 | $668.25K 10-Q · filed 2014-07-31 | $1.27M 10-Q · filed 2014-07-31 | |||
| 2013-03-31 | $605.94K 10-Q · filed 2014-05-09 | ||||
| 2012-12-31 | $2.18M 10-K · filed 2015-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |